The International Cancer Cluster Showcase (ICCS) was born back in 2011 in Washington DC, during the world’s largest biotech conference, BIO International Convention. International cluster managers and representatives from the oncology field in Boston, Toulouse and Oslo met during a networking reception and agreed to team up for a joint initiative to expose their emerging oncology innovators to the global oncology community gathering at BIO.
This idea matured in a stimulating and dynamic annual meeting featuring oncology innovators from several North American and European innovation hubs.
Exciting partnering opportunities
During the 6th edition of ICCS around 200 delegates learned about exciting partnering opportunities pitched by 24 companies from 9 innovation hubs.
Oslo Cancer Cluster was represented by its member companies Oncoimmunity AS and Nordic Nanovector. The two companies presented their preclinical and clinical candidates for treating hematological cancers. Inven2, Norway’ largest tech transfer organisation, gave a glimpse into their growing oncology portfolio.
An overwhelming amount of cutting edge oncology innovations from leading North American and European industry clusters were presented in compact presentations. Poster sessions, networking parts and a final reception allowed the participants to connect and discuss collaboration opportunities.
– I hope that the ICCS 2017 reception was as productive for the participating biotechs as the BIO reception in Washington 6 years ago was for the founders of ICCS, said Jutta Heix, International Advisor at Oslo Cancer Cluster and coordinator for the event.